Trial Profile
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose in 12-18 Months Old Healthy Children
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 2202083A (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Acronyms DTPA-HBV-IPV=HIB-MENC-TT-004 BST: 002
- Sponsors GlaxoSmithKline; GSK